Medication info
Dualetel Tablet 80/20 mg

Dualetel Tablet 80/20 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Widus Pharmaceuticals Co., Ltd.
Appearance
Pale pink oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 202104525 · Approved 2021.06.14

Summary

Main use
Treatment of hypertension and dyslipidemia, prevention of cardiovascular disease, and inhibition of atherosclerosis progression
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered in combination with a thiazide diuretic such as hydrochlorothiazide, it has an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be necessary. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams per day. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination with the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Widus Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia, prevention of cardiovascular disease, and inhibition of atherosclerosis progression

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attacks
  • clinical evidence of end-organ damage
  • high-risk diabetes
  • myocardial infarction
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
View approved original text

This medication is used for patients who require simultaneous administration of telmisartan and rosuvastatin. Telmisartan primarily helps in treating essential hypertension and reducing the risk of cardiovascular diseases. It is particularly effective in reducing the risk of myocardial infarction, stroke, and death from cardiovascular diseases in high-risk patients aged over 55 years. Rosuvastatin calcium is used to control hypercholesterolemia and hyperlipidemia as an adjunct when diet and exercise are insufficient. Additionally, it contributes to slowing the progression of atherosclerosis and reducing the risk of cardiovascular disease. Thus, this combination of medications effectively manages blood pressure and cholesterol, improving cardiovascular health.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered in combination with a thiazide diuretic such as hydrochlorothiazide, it has an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be necessary. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams per day. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination with the same amounts of each active ingredient) for convenience.

Precautions

This medication may cause serious harm or death to the fetus and newborn during pregnancy; therefore, it should be discontinued immediately if pregnancy is confirmed. Patients with hypersensitivity to this medication or who are pregnant, breastfeeding, or have severe liver or kidney disorders should not take it. Patients with a history of muscular disorders, elderly patients, those with hyperkalemia, or liver disorders should take this medication with caution, and regular monitoring and check-ups from a physician are necessary during treatment. This medication may affect liver and kidney function, so liver function tests and serum creatine kinase (CK) levels should be periodically checked before and during administration. If symptoms such as myalgia, muscle weakness, dizziness, or malaise occur during treatment, consult a physician immediately, and in severe cases, the medication may need to be discontinued. This medication may interact with other antihypertensives or lipid-lowering agents, so patients should inform their physician or pharmacist if they are taking other medications. Women who plan to become pregnant or are potentially pregnant should use appropriate contraceptive methods and avoid taking this medication during pregnancy. The safety and efficacy of this medication have not been established in children, so it is advisable not to use it in this population. In case of overdose, symptoms such as hypotension, dizziness, and renal failure may occur; therefore, patients should seek medical attention for appropriate treatment. Drowsiness or dizziness may occur during treatment, so caution should be exercised when driving or operating hazardous machinery. Store out of reach of children and do not transfer to another container for safety.

Side effects

Increased ALT, increased AST, increased blood creatine phosphokinase (CPK), dizziness, itching, dyspepsia, oral paresthesia, musculoskeletal stiffness, acne, nasopharyngitis, dysuria, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified intestinal disease, benign gastrointestinal tumors, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, hypotension, orthostatic hypotension, dyspnea, abdominal pain, diarrhea, abdominal bloating, vomiting, abdominal discomfort, dry mouth, liver function abnormality, liver dysfunction, increased sweating, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, back pain, muscle cramps, joint pain, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased blood creatinine, increased blood uric acid, increased liver enzymes, elevated blood CK, decreased hemoglobin, headache, facial spasms, sensory abnormalities, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, polyneuropathy, memory loss, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminase, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, joint pain, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive decline, forgetfulness, amnesia, memory impairment, confusion, severe muscle weakness, ocular muscle weakness, headache, constipation, nausea, pancreatitis, itching, rash, urticaria, myopathy, rhabdomyolysis, weakness, myalgia, increased CK, joint pain, numbness, sensory abnormalities, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal bloating, syncope, generalized pain, muscle cramps, gout, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is important to maintain ambient temperatures between 1 degree and 30 degrees celsius for storage. Proper storage can help maintain the medication's effectiveness for a longer duration.

Appearance and packaging

Appearance

Pale pink oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.